Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 5/2013

01-10-2013 | Viewpoint

Par-4 prevents breast cancer recurrence

Authors: Nikhil Hebbar, Tripti Shrestha-Bhattarai, Vivek M Rangnekar

Published in: Breast Cancer Research | Issue 5/2013

Login to get access

Abstract

Therapy resistance and disease recurrence are two of the most challenging aspects in breast cancer treatment. A recent article in Cancer Cell makes a significant contribution toward a better understanding of this therapeutic problem by establishing downregulation of the tumor suppressor Par-4 as the primary determinant of breast cancer recurrence. This viewpoint brings forth the importance of their findings and its implications on future research and therapy.
Literature
1.
Guarneri V, Dieci MV, Conte P: Relapsed triple-negative breast cancer: challenges and treatment strategies. Drugs. 2013, 73: 1257-1265. 10.1007/s40265-013-0091-6.CrossRefPubMed
2.
Theriault RL, Carlson RW, Allred C, Anderson BO, Burstein HJ, Edge SB, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Gradishar WJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Mankoff DA, Marcom PK, Mayer IA, McCormick B, Pierce LJ, Reed EC, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R: Breast cancer, version 3.2013. J Natl Compr Canc Netw. 2013, 11: 753-761.PubMedPubMedCentral
3.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63: 11-30. 10.3322/caac.21166.CrossRefPubMed
4.
Rea D, Tomlins A, Francis A: Time to stop operating on breast cancer patients with pathological complete response?. Eur J Surg Oncol. 2013, 39: 924-930. 10.1016/j.ejso.2013.06.005.CrossRefPubMed
5.
Pritchard KI: Endocrine therapy: is the first generation of targeted drugs the last?. J Intern Med. 2013, 274: 144-152. 10.1111/joim.12065.CrossRefPubMed
6.
Alvarez JV, Pan TC, Ruth J, Feng Y, Zhou A, Pant D, Grimley JS, Wandless TJ, Demichele A: I-SPY 1 TRIAL Investigators, Chodosh LA: Par-4 downregulation promotes breast cancer recurrence by preventing multinucleation following targeted therapy. Cancer Cell. 2013, 24: 30-44. 10.1016/j.ccr.2013.05.007.CrossRefPubMed
7.
8.
Méndez-López LF, Zapata-Benavides P, Zavala-Pompa A, Aguado-Barrera ME, Pacheco-Calleros J, Rodríguez-Padilla C, Cerda-Flores RM, Cortés-Gutiérrez EI, Dávila-Rodríguez MI: Immunohistochemical analysis of prostate apoptosis response-4 (Par-4) in Mexican women with breast cancer: a preliminary study. Arch Med Res. 2010, 41: 261-268. 10.1016/j.arcmed.2010.05.005.CrossRefPubMed
9.
Nagai MA, Gerhard R, Salaorni S, Fregnani JH, Nonogaki S, Netto MM, Soares FA: Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer. Int J Oncol. 2010, 37: 41-49.CrossRefPubMed
10.
Shrestha-Bhattarai T, Rangnekar VM: Cancer-selective apoptotic effects of extracellular and intracellular Par-4. Oncogene. 2010, 29: 3873-3880. 10.1038/onc.2010.141.CrossRefPubMed
11.
Pruitt K, Ulku AS, Frantz K, Rojas RJ, Muniz-Medina VM, Rangnekar VM, Der CJ, Shields JM: Ras-mediated loss of the pro-apoptotic response protein Par-4 is mediated by DNA hypermethylation through Raf-independent and Raf-dependent signaling cascades in epithelial cells. J Biol Chem. 2005, 280: 23363-23370. 10.1074/jbc.M503083200.CrossRefPubMed
12.
Ahmed MM, Sheldon D, Fruitwala MA, Venkatasubbarao K, Lee EY, Gupta S, Wood C, Mohiuddin M, Strodel WE: Downregulation of PAR-4, a pro-apoptotic gene, in pancreatic tumors harboring K-ras mutation. Int J Cancer. 2008, 122: 63-70. 10.1002/ijc.23019.CrossRefPubMed
13.
Lostumbo L, Carbine NE, Wallace J: Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010, 11: CD002748
Metadata
Title
Par-4 prevents breast cancer recurrence
Authors
Nikhil Hebbar
Tripti Shrestha-Bhattarai
Vivek M Rangnekar
Publication date
01-10-2013
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 5/2013
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr3562

Other articles of this Issue 5/2013

Breast Cancer Research 5/2013 Go to the issue

Research article

Association between mammographic density and basal-like and luminal A breast cancer subtypes

Research article

A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients

Research article

An optimized five-gene multi-platform predictor of hormone receptor negative and triple negative breast cancer metastatic risk

Research article

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer

Research article

A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous metastasis through IL-6 trans-signaling in a murine model

Research article

Breast cancer receptor status and stage at diagnosis in over 1,200 consecutive public hospital patients in Soweto, South Africa: a case series
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits